{"id":1341,"company":{"country":"DE","currency":"EUR","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2019-11-07","marketCap":36.50413131713867,"name":"Centogene NV","phone":"49038180113400.0","outstanding":27.8700008392334,"symbol":"CNTG","website":"https://www.centogene.com/","industry":"Health Care"},"price":1.29625,"year":2023,"month":11,"day":29,"weekday":"Wednesday","title":"Historical Performance of Centogene NV Stock during Economic Recessions and Recoveries","date":"2023-11-29","url":"/posts/2023/11/29/CNTG","content":[{"section":"Introduction","text":"Centogene NV is a biotechnology company that specializes in rare genetic diseases and diagnostics. As such, its stock performance may be influenced by economic cycles but could also be impacted by factors specific to the healthcare industry or its niche market. To analyze the historical performance of Centogene NV stock during economic recessions and recoveries, we will examine its stock price movements and key financial indicators during past periods of economic downturns and subsequent recoveries."},{"section":"Processing of Economic Recessions and Recoveries","text":"To determine the performance of Centogene NV stock during economic recessions and recoveries, we will identify major economic downturns and subsequent recoveries in recent history. This will involve examining macroeconomic data, such as GDP growth rates, national unemployment rates, and industry-specific indicators. By aligning these economic indicators with Centogene NV's stock price data, we can observe any correlations or patterns."},{"section":"Analysis of Centogene NV Stock Performance","text":"Using historical stock price data from reliable financial sources, we will analyze Centogene NV's stock price movements during identified economic recessions and recoveries. We will calculate relevant performance metrics such as total return, average annual return, and volatility during these periods. Additionally, we will compare Centogene NV's performance against relevant benchmarks, such as sector-specific indices or broader market indices."},{"section":"Contextual Factors","text":"To provide a comprehensive analysis, it is important to consider contextual factors that may have influenced Centogene NV's stock performance during economic recessions and recoveries. These factors may include company-specific developments, industry trends, regulatory changes, and market sentiment. By considering these factors, we can better understand the overall environment in which Centogene NV's stock has operated."},{"section":"Implications and Conclusions","text":"Based on the analysis of Centogene NV's historical performance during economic recessions and recoveries, we can draw conclusions regarding the stock's potential sensitivity to broader economic conditions. These findings may have implications for investors seeking to make informed decisions regarding Centogene NV's stock during future economic cycles."}],"tags":["CrossOver100","Long","Health Care"],"news":[{"category":"company","date":1701171000,"headline":"CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction","id":124148317,"image":"https://s.yimg.com/ny/api/res/1.2/PKOCgTCk73G8H7HWZAhkFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0yNDE-/https://media.zenfs.com/en/globenewswire.com/9b41a68a777599272aace0252a63ea1d","symbol":"CNTG","publisher":"Yahoo","summary":"Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing services to patients, health systems, biopharma clients, and research institutions across the Gulf Cooperation Council (GCC) region CENTOGENE to receive an additional $10 million upfront JV milestone payment, following an initial $30 million investment from Lifera. Company eligible for additional performance-related milestone payments and revenue-based royalt","url":"https://finance.yahoo.com/news/centogene-lifera-public-investment-fund-113000373.html"}]}